



Balfour Capital Group DexCom, Inc.

DexCom, Inc. is a leading American medical device company specializing in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, DexCom has revolutionized diabetes care with its innovative CGM technology, allowing real-time glucose monitoring without the need for fingerstick tests. Their product lineup includes the Dexcom G6 and G7 systems, as well as the over-the-counter Stelo CGM, catering to both insulin-dependent and non-insulin users.

1. Top 5 Competitors

DexCom operates in a competitive landscape with several key players:

1. Abbott Laboratories – Known for its FreeStyle Libre CGM systems.
2. Medtronic – Offers integrated insulin pumps and CGM devices.
3. Insulet Corporation – Specializes in tubeless insulin pump technology.
4. Roche – Provides a range of diabetes care solutions, including CGMs.
5. LifeScan – Develops blood glucose monitoring systems.

These companies are prominent in the diabetes technology sector, offering various solutions for glucose monitoring and insulin delivery.

2. Largest Institutional Shareholders

As of the latest data, the largest institutional shareholders of DexCom include:

- The Vanguard Group, Inc. – 12.1% ownership
- BlackRock, Inc. – 10.0% ownership
- State Street Global Advisors, Inc. – 4.25% ownership
- Capital Research and Management Company – 3.85% ownership
- Baillie Gifford & Co. – 3.62% ownership

Collectively, institutional investors hold approximately 97.75% of DexCom's outstanding shares.



Balfour Capital Group DexCom, Inc.

3. Management Team

DexCom's executive leadership includes:

- Kevin Sayer – Chairman, President & Chief Executive Officer
- Donald Abbey – Executive Vice President, Global Business Services, IT, Quality and Regulatory Affairs
- Michael Brown – Executive Vice President, Chief Legal Officer
- Jereme Sylvain – Executive Vice President, Chief Financial Officer
- Teri Lawver – Executive Vice President, Chief Commercial Officer

This team is responsible for steering DexCom's strategic direction and operational execution.

4. Revenue

DexCom reported a revenue of \$4.033 billion for the fiscal year 2024, marking an 11.34% increase from the previous year. For the first quarter of 2025, the company reported revenue of \$1.036 billion, representing a 12.49% year-over-year increase. The company projects total revenue of \$4.6 billion for the full year 2025, anticipating approximately 14% growth over 2024.

5. Institutions with Buy Recommendations:

Several financial institutions have issued buy recommendations for DexCom:

- Zacks Investment Research upgraded DexCom to a "Buy" rating, placing it in the top 20% of Zacks-covered stocks based on estimate revisions.



Balfour Capital Group DexCom, Inc.

6. Analyst Sentiment Summary

Analyst sentiment toward DexCom is generally positive:

- MarketBeat reports a consensus rating of "Moderate Buy" from 20 analysts, with 16 rating it as "Buy" or "Strong Buy," and 4 as "Hold."
- ChartMill indicates an 86% buy consensus among 33 analysts, with an average price target of \$101.15, suggesting a 19.69% upside from the current price.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, DexCom insiders have engaged in the following transactions:

- Shares Bought: 485,159
- Shares Sold: 172,684

This indicates a net buying activity among insiders during this period.
sider purchases during this period.